Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a “common language” for the new arena of cancer treatment
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a “common language” for the new arena of cancer treatment
Authors
Keywords
Progressive Disease, Tumor Burden, Measurement Variability, Unidimensional Measurement, Tumor Burden Increase
Journal
Journal for ImmunoTherapy of Cancer
Volume 4, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-05-12
DOI
10.1186/s40425-016-0134-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
- (2016) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment
- (2015) Mizuki Nishino et al. EUROPEAN JOURNAL OF RADIOLOGY
- Pseudoprogression and Immune-Related Response in Solid Tumors
- (2015) Victoria L. Chiou et al. JOURNAL OF CLINICAL ONCOLOGY
- Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma
- (2014) Luciano J. Costa et al. LEUKEMIA & LYMPHOMA
- State of the Art: Response Assessment in Lung Cancer in the Era of Genomic Medicine
- (2014) Mizuki Nishino et al. RADIOLOGY
- Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?
- (2014) Mizuki Nishino et al. Journal for ImmunoTherapy of Cancer
- Volumetric tumor growth in advanced non-small cell lung cancer patients withEGFRmutations during EGFR-tyrosine kinase inhibitor therapy
- (2013) Mizuki Nishino et al. CANCER
- Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements
- (2013) M. Nishino et al. CLINICAL CANCER RESEARCH
- Personalized Tumor Response Assessment in the Era of Molecular Medicine: Cancer-Specific and Therapy-Specific Response Criteria to Complement Pitfalls of RECIST
- (2012) Mizuki Nishino et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Change in Tumor Size by RECIST Correlates Linearly With Overall Survival in Phase I Oncology Studies
- (2012) Rajul K. Jain et al. JOURNAL OF CLINICAL ONCOLOGY
- Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors
- (2012) Mizuki Nishino et al. LUNG CANCER
- Variability of Lung Tumor Measurements on Repeat Computed Tomography Scans Taken Within 15 Minutes
- (2011) Geoffrey R. Oxnard et al. JOURNAL OF CLINICAL ONCOLOGY
- CT Tumor Volume Measurement in Advanced Non-small-cell Lung Cancer
- (2010) Mizuki Nishino et al. ACADEMIC RADIOLOGY
- Revised RECIST Guideline Version 1.1: What Oncologists Want to Know and What Radiologists Need to Know
- (2010) Mizuki Nishino et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Evaluating Variability in Tumor Measurements from Same-day Repeat CT Scans of Patients with Non–Small Cell Lung Cancer
- (2009) Binsheng Zhao et al. RADIOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More